+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Erectile Dysfunction Drugs Market by Sales Model (Branded, Generic), Treatment Duration (Long-Term, Short-Term), Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast 2025-2030- Product Image
Erectile Dysfunction Drugs Market by Sales Model (Branded, Generic), Treatment Duration (Long-Term, Short-Term), Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Erectile Dysfunction Drugs Market by Sales Model (Branded, Generic), Treatment Duration (Long-Term, Short-Term), Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989691
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The erectile dysfunction drugs market is evolving rapidly, driven by innovation in therapeutics, expanding patient demographics, and the integration of advanced digital health solutions. Senior leaders navigating this sector must anticipate shifts in clinical practice, policy, and supply chain strategies to harness current and emerging value pools.

Market Snapshot: Erectile Dysfunction Drugs Market Growth Trajectory

The erectile dysfunction drugs market grew from USD 2.59 billion in 2024 to USD 2.79 billion in 2025 and is projected to reach USD 3.99 billion by 2030, advancing at a CAGR of 7.44%. This growth is fueled by product innovation, broader patient demand, digital access transformation, and evolving global healthcare policies.

Scope & Segmentation: Mapping the Erectile Dysfunction Drugs Market

This report offers in-depth coverage of the erectile dysfunction therapeutics landscape, analyzing market performance by product type, distribution, regional adoption, and patient segmentation. Strategic focus areas include technology advancement and emerging trends that are influencing clinical and commercial decision-making.

  • Sales Models: Branded and generic drugs address the spectrum from innovative formulations to cost-effective alternatives, each occupying distinct market positions based on physician and patient needs.
  • Treatment Durations: Long-term and short-term therapies offer flexibility, with long-term options gaining relevance for those with chronic or persistent conditions, while short-term treatments focus on convenience and rapid effect.
  • Distribution Channels: Hospital pharmacies, online platforms, and retail outlets all play essential roles. Hospital channels maintain focus on cases with severe comorbidities, online channels emphasize privacy and accessibility, and retail channels cater to broad, immediate access.
  • Dosage Strengths: Varied strengths (100 Mg, 50 Mg, 25 Mg) reflect differing clinical needs, spanning established regimens and those tailored for lower systemic exposure or heightened patient safety.
  • Patient Age Groups: Segments include patients aged 40–60 years prioritizing quality of life, those over 60 emphasizing comorbidity management, and under-40 populations seeking discreet, rapid solutions for psychological or lifestyle-related factors.
  • Regional Coverage: Americas (notably United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., UK, Germany, France, UAE, South Africa), Asia-Pacific (including China, India, Japan, Australia, South Korea, among others) are evaluated for uptake trends and market access.
  • Leading Companies: Pfizer Inc., Eli Lilly and Company, Bayer AG, Teva Pharmaceutical, Viatris Inc., Sandoz International GmbH, Dr. Reddy's, Sun Pharma, Aurobindo Pharma, Cipla Limited represent strategic innovators and established players.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovation is increasingly shaped by molecular advancements and targeted drug delivery, resulting in more personalized and effective options for diverse patient groups.
  • Digital health integration, including telemedicine and mobile adherence tools, is fundamental for expanding reach and enhancing patient engagement in a highly sensitive therapeutic area.
  • Evolving patient demographics, with younger segments seeking treatment, require refreshed marketing strategies and emphasis on education and adherence support.
  • Supply chain resilience and local manufacturing investments are core responses to global disruptions such as shifting tariffs and trade policies.
  • Collaboration between pharmaceutical manufacturers, digital solution providers, and healthcare professionals is central to real-world evidence generation and continuous product optimization.

Tariff Impact: Navigating United States 2025 Policy Changes

New U.S. tariffs in 2025 are reshaping global supply chains. Manufacturers facing higher input costs are turning to local sourcing and production diversification. Companies are adapting pricing strategies, often balancing cost absorption with selective adjustments, while prioritizing resilient supply networks. These measures limit patient impact and safeguard competitive positioning in a dynamic trade landscape.

Methodology & Data Sources

Our comprehensive analysis uses multi-stage research, synthesizing desk reviews of clinical trials, regulatory filings, and scientific literature with primary interviews from key opinion leaders. Triangulation with corporate reports, transactional benchmarks, and patent data ensures robust, unbiased insights. Market segmentation reflects in-depth exploration of sales models, treatment durations, regional dynamics, and patient characteristics.

Erectile Dysfunction Drugs Market: Why This Report Matters

  • Enables informed strategic planning by detailing critical growth drivers, regulatory requirements, and disruptive technology trends shaping the market.
  • Delivers targeted, actionable intelligence to guide investment, portfolio optimization, and risk management in a highly regulated sector.
  • Supports cross-functional teams with segmented data and strategic recommendations aligned with real-world challenges and opportunities for commercial success.

Conclusion

This report equips industry leaders with the insights and frameworks needed to navigate the evolving erectile dysfunction drugs market. Stakeholders can leverage these findings to drive growth, reinforce resilience, and advance patient outcomes in a complex healthcare landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of over-the-counter low-dose sildenafil and tadalafil formulations boosting market accessibility
5.2. Integration of telemedicine platforms with direct-to-consumer erectile dysfunction prescriptions and digital health monitoring
5.3. Increasing focus on personalized medicine through genetic profiling for erectile dysfunction drug efficacy optimization
5.4. Development of novel nitric oxide donor compounds and alternative delivery methods like sublingual films and nasal sprays
5.5. Impact of patent expirations on branded PDE5 inhibitors fueling intensified generic competition and price erosion
5.6. Growing interest in regenerative therapies combining stem cell treatments with conventional ED pharmacotherapy
5.7. Expansion of erectile dysfunction treatment indications to address comorbid conditions like pulmonary hypertension and benign prostatic hyperplasia
5.8. Influence of lifestyle modification initiatives integrated with pharmacotherapy on patient adherence and long-term outcomes
5.9. Emergence of peptide-based therapeutics targeting alternative erectile pathways beyond conventional PDE5 inhibition
5.10. Regulatory approvals of next-generation PDE5 inhibitors with enhanced safety profiles and minimal drug interactions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Erectile Dysfunction Drugs Market, by Sales Model
8.1. Introduction
8.2. Branded
8.3. Generic
9. Erectile Dysfunction Drugs Market, by Treatment Duration
9.1. Introduction
9.2. Long-Term
9.3. Short-Term
10. Erectile Dysfunction Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Erectile Dysfunction Drugs Market, by Dosage Strength
11.1. Introduction
11.2. 100 Mg
11.3. 25 Mg
11.4. 50 Mg
12. Erectile Dysfunction Drugs Market, by Patient Age Group
12.1. Introduction
12.2. 40-60 Years
12.3. 60+ Years
12.4. Under 40 Years
13. Americas Erectile Dysfunction Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Erectile Dysfunction Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Erectile Dysfunction Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Eli Lilly and Company
16.3.3. Bayer AG
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. Viatris Inc.
16.3.6. Sandoz International GmbH
16.3.7. Dr. Reddy's Laboratories Ltd.
16.3.8. Sun Pharmaceutical Industries Ltd.
16.3.9. Aurobindo Pharma Limited
16.3.10. Cipla Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ERECTILE DYSFUNCTION DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ERECTILE DYSFUNCTION DRUGS MARKET: RESEARCHAI
FIGURE 26. ERECTILE DYSFUNCTION DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ERECTILE DYSFUNCTION DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ERECTILE DYSFUNCTION DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 70. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 71. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 72. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 73. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 76. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 77. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 80. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 81. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 82. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 83. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 86. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 87. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 88. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 132. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 133. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 134. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 135. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 138. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 139. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 142. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 143. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 144. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 145. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 162. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 163. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 164. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 165. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 172. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 173. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 174. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 175. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 178. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 179. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 212. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 213. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 214. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 215. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 218. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 219. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 232. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 233. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 234. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 235. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 238. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 239. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 242. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 243. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 244. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 245. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 248. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 249. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 272. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 273. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 274. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 275. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 282. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 283. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 284. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 285. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 288. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 289. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 302. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 303. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 304. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 305. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 308. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 309. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 312. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (US

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.99 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Erectile Dysfunction Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Erectile Dysfunction Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 81 Pages
  • Global
From
Erectile Dysfunction (ED) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033 - Product Image

Erectile Dysfunction (ED) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • Report
  • 180 Pages
  • Global
From
Drugs for Erectile Dysfunction Market Report 2025 - Product Image

Drugs for Erectile Dysfunction Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Erectile Dysfunction Drugs - Global Strategic Business Report - Product Image

Erectile Dysfunction Drugs - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From

About the Erectile Dysfunction Drug Market

The Erectile Dysfunction Drug market is a subset of the Sexual and Reproductive Health Drugs market. These drugs are used to treat erectile dysfunction, a condition in which a man is unable to achieve or maintain an erection sufficient for sexual intercourse. Common treatments include phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil, as well as testosterone replacement therapy. These drugs are typically prescribed by a doctor and can be taken orally or injected directly into the penis. The Erectile Dysfunction Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Pfizer, Eli Lilly, Bayer, Merck, and GlaxoSmithKline. Other companies include Teva Pharmaceuticals, Sun Pharmaceuticals, and Cipla. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.